Capella Imaging

Executive Summary

Capella Imaging is a San Francisco-based biogenerator company pioneering novel diagnostic imaging agents for unmet medical needs. Founded in 2019, the company's lead candidate, FibroScint, is a fibrin-targeted SPECT imaging agent designed to detect blood clots (thrombus) in cardiovascular conditions. The initial target population is patients with left ventricular assist devices (LVADs), who are at high risk for thrombotic complications. Current diagnostic methods for LVAD-associated thrombus are invasive or lack sensitivity, creating a clear clinical need for a non-invasive, specific imaging approach. FibroScint leverages fibrin as a biomarker for active clot formation, potentially enabling early detection and improved management of thromboembolic events. By addressing a critical gap in cardiovascular diagnostics, Capella Imaging aims to reduce morbidity and mortality in vulnerable patient populations. The company's focus on capital-efficient development and strategic partnerships positions it to advance its pipeline into clinical trials. With a strong foundation in nuclear imaging and a targeted therapeutic strategy, Capella Imaging is poised to validate its platform and attract further investment.

Upcoming Catalysts (preview)

• Q2 2026FDA IND clearance for FibroScint first-in-human trial65% success
• Q4 2026Presentation of preclinical efficacy data at a major cardiovascular conference70% success
• TBDStrategic partnership with a LVAD manufacturer for co-development40% success